NRX Pharmaceuticals (NRXP) Asset Utilization Ratio (2025 - 2026)

NRX Pharmaceuticals (NRXP) posted quarterly Asset Utilization Ratio of 0.18 for Q1 2026, up 116.15% quarter-over-quarter from 0.08 in Q4 2025.

NRX Pharmaceuticals (NRXP) Asset Utilization Ratio (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has reported Asset Utilization Ratio for 2 consecutive years, with 0.18 the latest figure, recorded in Q1 2026.

In Q1 2026, Asset Utilization Ratio changed N/A year-over-year to 0.18; the TTM figure through Mar 2026 stood at 0.18 (changed N/A YoY), while the FY2025 annual figure was 0.14, changed N/A from the prior year.
Asset Utilization Ratio rose to 0.18 in Q1 2026 per NRXP's latest filing, from 0.08 in the prior quarter.
Across five years, Asset Utilization Ratio topped out at 0.18 in Q1 2026 and bottomed at 0.02 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.38
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.20
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.69
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.90
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.13
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.54
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.13
10	NRX Pharmaceuticals	132.53 Mn	105.83 Mn	426,000.00	0.15

Download Data